Clinical implications of lymph node micrometastasis in patients with histologically node-negative (pNO) esophageal carcinoma

Clinical implications of lymph node micrometastasis in patients with histologically node-negative (pNO) esophageal carcinoma
复制标题

DOI:
10.1002/jso.10080
复制
发表时间:
2002-04-01
影响因子:
2.5
通讯作者:
Takasaki, K
Takasaki, K
中科院分区:
医学3区
文献类型:
--
作者:
Nakamura, T;Ide, H;Takasaki, K

文献摘要

被引文献

相似文献

背景与目的:在食管鳞状细胞癌(ESCC)的切除标本中经常检测到淋巴结微转移。本研究的目的是评估微转移在淋巴结阴性(pN0)疾病患者中的临床意义。方法:我们对53例接受根治性食管切除术的pN0患者的2511个淋巴结进行了微转移检查。使用抗细胞角蛋白抗体鸡尾酒(AE1/AE3)对所有淋巴结和原发肿瘤进行免疫染色。结果:14例(26.4%)患者中18例(0.72%)淋巴结有微转移。微转移的检测与浸润深度、分化或淋巴浸润无关。含有微转移的淋巴结分布广泛,但最常累及的淋巴结位于胃小弯。有微转移者4例(29%),无微转移者2例(5%)以淋巴结转移复发(P=0.036)。微转移患者和无微转移患者的无复发生存期和疾病特异性生存期无显著差异。结论:微转移可能增加淋巴结复发的风险,但不影响pN0 ESCC患者的生存。
Background and Objectives: Lymph node micrometastasis is frequently detected in resected specimens of esophageal squamous cell carcinoma (ESCC). The goal of this study was to evaluate the clinical implication of micrometastasis in patients with lymph node-negative (pN0) disease.Methods: We examined the presence of micrometastasis in 2,511 lymph nodes from 53 patients with pN0 disease who underwent curative esophagectomy. All lymph nodes and the primary tumors were immunostained using an anticytokeratin antibody cocktail (AE1/AE3).Results: Micrometastasis was detected in 18 lymph nodes (0.72%) from 14 patients (26.4%). Detection of micrometastasis was not associated with the depth of invasion or the differentiation or lymphatic invasion. Lymph nodes containing micrometastases were widely distributed, but the most frequently involved nodes were located along the lesser curvature of the stomach. Four patients with micrometastasis (29%) and the only two patients without micrometastasis (5%) had recurrence as lymph node metastases (P=0.036). There were no significant differences in recurrence-free survival and disease-specific survival between patients with micrometastasis and patients without micrometastasis.Conclusions: These results show that micrometastasis might increase the risk of lymph node recurrence, but does not influence the survival of patients with pN0 ESCC.